Edible Garden AG's CEO Jim Kras will speak at the 2026 CEAg World Conference & Expo about expanding beyond core controlled environment agriculture (CEA). He will highlight the company's use of proprietary technologies and partnerships with Square Roots and Caney Fork Farms to grow into value-added foods, clean-label nutrition, and ready-to-drink beverages. This strategy aims to diversify revenue streams and leverage innovation in agriculture and product development. The event will focus on practical strategies for profitability and growth in the CEA sector.
Edible Garden CEO Jim Kras's upcoming talk on innovation and diversification provides context for readers following the Consumer Staples sector. For readers following Consumer Staples, here is Pluang's market snapshot as of Nov 02, 2026 19:12 WIB: Among 63 priced US stocks, 30 rose and 19 fell. Notable prices include DNUT (Krispy Kreme Inc) at USD 3.25 with a -0.76% change and a typical hold time of 47 days, COUR (Coursera Inc) at USD 3.50 with a +0.72% change and a typical hold time of 48 days, and SYY (SYSCO Corporation) at USD 82.38 with a -0.60% change and a typical hold time of 79 days.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
